# US 11,788,146 B2 · Methods for therapeutics prescreening in bodily fluids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,788,146 B2
- Document ID: US11788146B2
- Status: Granted
- Kind: B2
- Application number: 16/628,210
- Filed: 2018-07-05
- Published: 2020-07-09
- Granted: 2023-10-17
- Earliest claimed: 2017-07-06
- Assignees: Barcode Diagnostics Ltd.
- Applicants: Barcode Diagnostics Ltd.
- Inventors: Ronen Eavri; Annie Sabbah; Felix Badinter; Raphael Tshuva; Avi Schroeder
- Web page: https://patentgrep.com/patent/US11788146B2

## CPC

- C12Q 1/68: involving nucleic acids
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 49/00: Preparations for testing in vivo
- A61K 49/0017: {Fluorescence in vivo}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method for using bodily fluids in determining the cell-specific potency of drugs is provided. A composition comprising a plurality of types of carriers, wherein each carrier comprises a single-cell lethal amount of a therapeutic agent and a unique barcode identifying that agent and wherein the composition comprises equal numbers of each carrier type, equal concentrations of the agent and equal concentrations of each barcode is also provided. Further, methods useful for studying the therapeutic profile of one or more drugs within a cell microenvironment, including but not limited to a tumor, are provided.

## Claims

### Claim 1

A method for predicting response of a subject afflicted with cancer to at least one therapeutic agent of a plurality of therapeutic agents, the method comprising the steps of:
(a) administering to the subject a composition comprising a plurality of types of carriers and said plurality of therapeutic agents, wherein each carrier is selected from a nanoparticle and a liposomal membrane and each type of carrier independently comprises between 0.1 and 10% of an effective therapeutic dose (ETD) of a different at least one therapeutic agent from among said plurality of therapeutic agents and one or more nucleic acid barcodes uniquely identifying said different at least one therapeutic agent from among said plurality of therapeutic agents;
(b) obtaining a fluid sample from said subject, wherein said fluid is selected from the group consisting of: blood, plasma, serum, saliva, lymph, urine, breast milk, cerebral spinal fluid and seminal fluid; and
(c) detecting, in said fluid, at least one of said unique nucleic acid barcodes of one type of carrier, wherein the presence of said unique nucleic acid barcode in said fluid indicates said subject's cancer responds to said different at least one therapeutic agent from among said plurality of therapeutic agents identified by said detected unique nucleic acid barcode;
thereby predicting response of a subject afflicted with cancer to at least one therapeutic agent of a plurality of therapeutic agents.

### Claim 2 (depends on 1)

The method of claim 1, wherein said composition comprises a substantially equal number of each type of carrier, wherein substantially equal is a variance of less than 10%.

### Claim 3 (depends on 1)

The method of claim 1, wherein each type of carrier comprises a substantially equal barcode concentration wherein substantially equal is a variance of less than 10%.

### Claim 4 (depends on 1)

The method of claim 1, wherein each type of carrier comprises a substantially equal concentration of said different at least one therapeutic agent from among said plurality of therapeutic agents relative to an effective therapeutic dose (ETD) of said different at least one therapeutic agent from among said plurality of therapeutic agents, wherein substantially equal is a variance of less than 10%.

### Claim 5 (depends on 1)

The method of claim 1, wherein said administering is intravenous injection and said composition comprises 1-200 of each type of carrier per a single disease cell of said subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein said administering is intratumoral injection, and said composition comprises 1-20 of each type of carrier per a single disease cell of said subject.

### Claim 7 (depends on 1)

The method of claim 1, wherein said obtaining is performed within a time frame of 48-192 hours following said administering of said composition.

### Claim 8 (depends on 1)

The method of claim 1, wherein said detecting comprises sequencing said nucleic acid barcode, amplifying said nucleic acid barcode, or both.

### Claim 9 (depends on 1)

The method of claim 1, wherein said fluid is blood.

### Claim 10 (depends on 1)

The method of claim 1, further comprising removing intact cells from said fluid sample before step (c).

### Claim 11 (depends on 1)

The method of claim 1, further comprising removing intact carrier from said fluid sample before step (c).

### Claim 12 (depends on 1)

The method of claim 1, wherein said at least one carrier further comprises a tag.

### Claim 13 (depends on 1)

The method of claim 1, wherein said unique barcode comprises a cleavage site specific to a nuclease specific to said cancer.

### Claim 14 (depends on 1)

The method of claim 1, wherein said unique barcode comprises a cleavage site specific to a nuclease with cytoplasmic localization in a cell of said disease.

### Claim 15 (depends on 1)

The method of claim 1, wherein each type of carrier comprises between 0.1% and 5% of the ETD of said different at least one therapeutic agent from among said plurality of therapeutic agents.

### Claim 16 (depends on 1)

The method of claim 1, wherein said detecting is detecting cell free DNA barcodes.
